US-based precision oncology company Guardant Health has teamed up with Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Italy to enhance liquid biopsy testing.
The collaboration aims to establish an in-house liquid biopsy testing service as a part of Policlinico Gemelli’s diagnostics services within its hospital system.
It will leverage Guardant’s advanced digital sequencing platform and include on-site analysis of Guardant360 CDx liquid biopsy tests within Policlinico Gemelli facilities in Rome, Italy.
The partnership will address the clinical research and patient care needs and enable one of Italy’s first dedicated liquid biopsy testing facilities within a hospital system.
Policlinico Gemelli scientific director Giovanni Scambia said: “Gemelli, one of the most important Italian and European oncology centres, can now offer its patients more state-of-the-art diagnostics for precision oncology through this innovative test.”
Policlinico Gemelli is one of Italy’s largest hospitals and serves thousands of cancer patients each year at its comprehensive cancer centre.
The facility offers advanced oncology services, including diagnostics, treatment, and research.
Guardant Health provides diagnostic tests that are used by oncologists worldwide to guide treatment decisions across solid tumour cancers.
Pharmaceutical companies and academic researchers also use the company’s test in clinical trials to advance precision medicine drug development.
Earlier this year, Guardant Health received regulatory certification for its Guardant360 CDx blood test in the European Union (EU), under the In Vitro Diagnostic Regulation (IVDR).
Guardant360 CDx is indicated for tumour mutation profiling in cancer patients and as a companion diagnostic to identify patients who may benefit from certain targeted therapies.
Guardant Health co-CEO Helmy Eltoukhy said: “We’re thrilled to partner with Policlinico Gemelli, empowering clinicians to swiftly detect tumour alterations with a blood test, guiding personalised treatments, and fuelling research innovation.
“This collaboration brings us closer to our mission of ensuring all cancer patients worldwide have access to the latest advancements for optimal care.”